Clinical trials
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia clinical trials
Below are recruiting relapsed or refractory b-cell acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 1,758 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05754684RecruitingPhase 2
Immunotherapy with donor NK cells for relapsed neuroblastoma
This trial studies a “quadruple immunotherapy” treatment using donor immune cells (NK cells) to fight neuroblastoma that has come back or did not respond to prior therapy. It may help by boosting the body’s immune attack, but only certain children meet the safety and donor requirements.
Hong KongAges Up to 18 years - NCT06421675RecruitingPhase 2
Elranatamab for multiple myeloma that has come back
This trial tests a new drug called elranatamab (given as an outpatient, not in the hospital) for people with multiple myeloma that has come back or stopped responding to several treatments. The goal is to see if taking it less often works well and is safer.
Vancouver, British ColumbiaAges 18 years+ - NCT06432465Recruiting
Brain stimulation to help prevent opioid relapse
This study uses a type of brain stimulation called tDCS (transcranial direct current stimulation) to see if it can help people who have recently started medication for opioid dependence (buprenorphine or methadone) stay on track and avoid relapse. The treatment is non-invasive and involves a mild electrical current applied to the scalp.
Providence, Rhode IslandAges 21–60 - NCT06427941RecruitingPhase 1/Phase 2
Study of BGB-B2033 with other drugs for advanced solid tumors
This study tests a new drug called BGB-B2033, alone or with other drugs (tislelizumab and bevacizumab), in people with certain advanced cancers. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
Birmingham, AlabamaAges 18 years+ - NCT05962177Recruiting
Study of blood tests and scans in relapsing-remitting MS
This study follows adults with relapsing-remitting multiple sclerosis using MRI scans and blood tests. It aims to understand how the disease behaves and what markers in blood and imaging may relate to changes over time.
MontpellierAges 18–59 - NCT06017518Recruiting
Watching local relapse after high-grade osteosarcoma treatment
This study is watching people whose high-grade osteosarcoma came back in the same bone area (local relapse) after treatment. It helps doctors understand how local relapse happens, so they can improve future care.
Bologna, BOAges Any age - NCT06348797RecruitingPhase 1
CAR-T Cells Targeting PD-L1 and DLL3 for Small Cell Lung Cancer
This trial tests a new CAR-T cell therapy that targets two proteins (PD-L1 and DLL3) on small cell lung cancer cells. It's for people whose cancer came back or got worse after standard chemotherapy, and it aims to see if the treatment is safe and works.
Chengdu, SichuanAges 18–70 - NCT04121468RecruitingPhase 1/Phase 2
Metformin trial for vision nerve recovery in young people with MS
This study tests whether metformin can help “reset” damaged nerve cells in the brain and improve vision-related nerve problems in children and young adults with multiple sclerosis. Participants are assigned to metformin or a comparison treatment in a blinded (not everyone knows which) study.
Toronto, OntarioAges 10–25 - NCT06320405RecruitingPhase 1/Phase 2
Combination therapy for advanced solid tumors
This trial tests a combination of three drugs—axatilimab, retifanlimab, and paclitaxel—for people with advanced solid tumors that have spread. It aims to see if this combination can shrink tumors or slow their growth, and it is for people who have already tried taxane chemotherapy.
Portland, OregonAges 18 years+ - NCT05964829Recruiting
Test a leg sleeve to improve walking in multiple sclerosis
This trial studies whether using the Cionic “Neural Sleeve” can improve walking and leg movement in people with multiple sclerosis (MS). It may help if your MS affects mobility, and you can safely wear and tolerate the device during the day.
Cleveland, OhioAges 22–75 - NCT06285279RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune kidney diseases
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
Nanjing, JiangsuAges 18–65 - NCT06285825RecruitingPhase 2
Study of emapalumab for low blood counts after CAR T-cell therapy
This study tests a drug called emapalumab to help people whose blood counts stay low for weeks after CAR T-cell therapy for certain types of lymphoma. The goal is to see if the drug can help the body recover normal blood cell production.
Houston, TexasAges 18 years+ - NCT06233110RecruitingPhase 1
Ruxolitinib and fostamatinib for steroid-resistant chronic GVHD
This study tests two drugs, ruxolitinib and fostamatinib, together for people with chronic graft-versus-host disease (GVHD) that hasn't responded well to steroids. The goal is to see if this combination can better control GVHD.
Durham, North CarolinaAges 18–80 - NCT06245434Recruiting
Circadian rhythms during coma awakening
This study looks at how the body's internal clock (circadian rhythm) changes as people wake up from a coma. Researchers hope to learn more about recovery patterns to improve care for patients with brain injuries.
Bron, LyonAges 17 years+ - NCT06244641Recruiting
New Model for Relapse in Alcohol Use Disorder
This study is testing a new way to understand and predict relapse in people with alcohol use disorder. If you're currently hospitalized for this condition, researchers want to learn from your experience to improve care.
Brussels, Brussels CapitalAges 18 years+ - NCT06223542RecruitingPhase 1
TAK-243 for advanced cancers that haven't responded to other treatments
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
Bethesda, MarylandAges 18 years+ - NCT06225505Recruiting
Early detection of triple-negative breast cancer return
This trial uses blood tests to look for signs of cancer returning early in women who had triple-negative breast cancer. If caught early, doctors can start treatment sooner.
AvignonAges 18 years+ - NCT06207799RecruitingPhase 2
Drug combo before and after transplant for high-risk myeloma
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
Houston, TexasAges 18–75 - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT06141070RecruitingPhase 3
Adding high-dose radiation to standard treatment for advanced lung cancer
This trial tests whether adding a high, focused dose of radiation to the usual first treatment (chemo and/or immunotherapy) can help people with non-small cell lung cancer that has spread to a limited number of spots (up to 5). The goal is to see if this approach improves how well the treatment works.
GothenburgAges 18 years+ - NCT06122389RecruitingPhase 3
Study of SHR2554 for T-cell lymphoma
This trial tests a new drug called SHR2554 (compared to chidamide) for T-cell lymphoma that has not responded to or come back after prior treatment. It's a Phase 3 study to see if the drug can help control the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT06112067Recruiting
Brain implant for severe mental health conditions
This trial tests a brain implant called deep brain stimulation (DBS) for people with severe mental health conditions that have not improved with usual treatments. The goal is to see if it can reduce symptoms and improve quality of life.
ShanghaiAges 18–65 - NCT06118502Recruiting
Adaptive quit-smoking treatment for early relapse
This trial tests a flexible treatment approach for smokers who want to quit and are at risk of relapsing early. It aims to help you stay smoke-free by adjusting the support you get.
Charleston, South CarolinaAges 21 years+ - NCT06084936RecruitingPhase 3
Glofitamab alone vs other treatments for mantle cell lymphoma
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
Berkeley, CaliforniaAges 18 years+
Hear when a new Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 1,758 recruiting relapsed or refractory b-cell acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- Relapsed/Refractory Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- T-cell Acute Lymphoblastic Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Malignancies
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.